...Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic...
https://eipm.weill.cornell.edu/publications?page=7&s=type&o=asc
...Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic...
https://eipm.weill.cornell.edu/publications?page=7&s=title&o=asc
...Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic...
https://eipm.weill.cornell.edu/publications?page=29&s=type&o=desc
...Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic...
https://eipm.weill.cornell.edu/publications?page=29&s=title&o=desc
...Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.....
https://eipm.weill.cornell.edu/publications?page=26&s=type&o=asc
...Thus, the clinical benefit of metformin in PCa may depend on the status of NKX3.1 expression....
https://pathology.weill.cornell.edu/research/publications/metformin-overcomes-consequences-nkx31-loss-suppress-prostate-cancer
...Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.....
https://eipm.weill.cornell.edu/publications?page=26&s=title&o=asc
...Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic...
https://eipm.weill.cornell.edu/publications?page=22&s=year&o=desc
...Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.....
https://eipm.weill.cornell.edu/publications?page=19&s=year&o=desc
...Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.....
https://eipm.weill.cornell.edu/publications?page=10&s=type&o=desc
